260 related articles for article (PubMed ID: 34927282)
1. Schisandrin B ameliorates non-alcoholic liver disease through anti-inflammation activation in diabetic mice.
Ma R; Zhan Y; Zhang Y; Wu L; Wang X; Guo M
Drug Dev Res; 2022 May; 83(3):735-744. PubMed ID: 34927282
[TBL] [Abstract][Full Text] [Related]
2. [Effect of Danlou Tablets on alleviating hepatic adipogenesis, inflammatory response, and insulin resistance in db/db mice].
Pang YF; Huang M; Li L; Zhao X; Zhang HX; Li YH
Zhongguo Zhong Yao Za Zhi; 2022 Jun; 47(12):3320-3327. PubMed ID: 35851126
[TBL] [Abstract][Full Text] [Related]
3. Melatonin ameliorates hepatic steatosis by inhibiting NLRP3 inflammasome in db/db mice.
Yu Y; Chen D; Zhao Y; Zhu J; Dong X
Int J Immunopathol Pharmacol; 2021; 35():20587384211036819. PubMed ID: 34399601
[TBL] [Abstract][Full Text] [Related]
4. Crocin ameliorates hepatic steatosis through activation of AMPK signaling in db/db mice.
Luo L; Fang K; Dan X; Gu M
Lipids Health Dis; 2019 Jan; 18(1):11. PubMed ID: 30621686
[TBL] [Abstract][Full Text] [Related]
5. Schisandrin B mitigates hepatic steatosis and promotes fatty acid oxidation by inducing autophagy through AMPK/mTOR signaling pathway.
Yan LS; Zhang SF; Luo G; Cheng BC; Zhang C; Wang YW; Qiu XY; Zhou XH; Wang QG; Song XL; Pan SY; Zhang Y
Metabolism; 2022 Jun; 131():155200. PubMed ID: 35405150
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effect of schisandrin B on free fatty acid-induced steatosis in L-02 cells.
Chu JH; Wang H; Ye Y; Chan PK; Pan SY; Fong WF; Yu ZL
World J Gastroenterol; 2011 May; 17(19):2379-88. PubMed ID: 21633637
[TBL] [Abstract][Full Text] [Related]
7. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease.
Liu X; Chen S; Zhang L
Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E34-E42. PubMed ID: 32228319
[TBL] [Abstract][Full Text] [Related]
8. Topical rhubarb charcoal-crosslinked chitosan/silk fibroin sponge scaffold for the repair of diabetic ulcers improves hepatic lipid deposition in db/db mice via the AMPK signalling pathway.
Tan Q; He Q; Peng Z; Zeng X; Liu Y; Li D; Wang S; Wang J
Lipids Health Dis; 2024 Feb; 23(1):52. PubMed ID: 38378566
[TBL] [Abstract][Full Text] [Related]
9. Extracts from Aralia elata (Miq) Seem alleviate hepatosteatosis via improving hepatic insulin sensitivity.
Hwang KA; Hwang YJ; Kim GR; Choe JS
BMC Complement Altern Med; 2015 Oct; 15():347. PubMed ID: 26438035
[TBL] [Abstract][Full Text] [Related]
10. Alisol A 24-Acetate Prevents Hepatic Steatosis and Metabolic Disorders in HepG2 Cells.
Zeng L; Tang W; Yin J; Feng L; Li Y; Yao X; Zhou B
Cell Physiol Biochem; 2016; 40(3-4):453-464. PubMed ID: 27889747
[TBL] [Abstract][Full Text] [Related]
11. Canagliflozin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism and Inhibiting Inflammation through Induction of Autophagy.
Xu Z; Hu W; Wang B; Xu T; Wang J; Wei D
Yonsei Med J; 2022 Jul; 63(7):619-631. PubMed ID: 35748073
[TBL] [Abstract][Full Text] [Related]
12. Kaempferol attenuates nonalcoholic fatty liver disease in type 2 diabetic mice via the Sirt1/AMPK signaling pathway.
Li N; Yin L; Shang J; Liang M; Liu Z; Yang H; Qiang G; Du G; Yang X
Biomed Pharmacother; 2023 Sep; 165():115113. PubMed ID: 37418974
[TBL] [Abstract][Full Text] [Related]
13. Kukoamine A attenuates insulin resistance and fatty liver through downregulation of Srebp-1c.
Li G; Zhou F; Chen Y; Zhang W; Wang N
Biomed Pharmacother; 2017 May; 89():536-543. PubMed ID: 28254666
[TBL] [Abstract][Full Text] [Related]
14. Schizandrin A supplementation improves nonalcoholic fatty liver disease in mice fed a high-fat and high-cholesterol diet.
Jeong MJ; Kim SR; Jung UJ
Nutr Res; 2019 Apr; 64():64-71. PubMed ID: 30802724
[TBL] [Abstract][Full Text] [Related]
15. Chinese herbal medicine mixture 919 syrup alleviates nonalcoholic fatty liver disease in rats by inhibiting the NF-κB pathway.
Chen M; Xing J; Pan D; Peng X; Gao P
Biomed Pharmacother; 2020 Aug; 128():110286. PubMed ID: 32521450
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of long non-coding RNA Gm10804 suppresses disorders of hepatic glucose and lipid metabolism in diabetes with non-alcoholic fatty liver disease.
Li T; Huang X; Yue Z; Meng L; Hu Y
Cell Biochem Funct; 2020 Oct; 38(7):839-846. PubMed ID: 32212193
[TBL] [Abstract][Full Text] [Related]
17. Lipidomic-based investigation into the regulatory effect of Schisandrin B on palmitic acid level in non-alcoholic steatotic livers.
Kwan HY; Niu X; Dai W; Tong T; Chao X; Su T; Chan CL; Lee KC; Fu X; Yi H; Yu H; Li T; Tse AK; Fong WF; Pan SY; Lu A; Yu ZL
Sci Rep; 2015 Mar; 5():9114. PubMed ID: 25766252
[TBL] [Abstract][Full Text] [Related]
18. A multi-targeting strategy to ameliorate high-fat-diet- and fructose-induced (western diet-induced) non-alcoholic fatty liver disease (NAFLD) with supplementation of a mixture of legume ethanol extracts.
Koh YC; Lin YC; Lee PS; Lu TJ; Lin KY; Pan MH
Food Funct; 2020 Sep; 11(9):7545-7560. PubMed ID: 32815965
[TBL] [Abstract][Full Text] [Related]
19. [Effect of Fuzi Lizhong decoction in reducing liver injury of rats with non-alcoholic fatty liver via activating AMPK and suppressing NF-κBp65 pathway].
Yang JY; Shi ZH; Ma W; Tao DQ; Liu S; Chen L; Zhou XL
Zhongguo Zhong Yao Za Zhi; 2018 Aug; 43(15):3176-3183. PubMed ID: 30200715
[TBL] [Abstract][Full Text] [Related]
20. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
Zhu X; Bian H; Wang L; Sun X; Xu X; Yan H; Xia M; Chang X; Lu Y; Li Y; Xia P; Li X; Gao X
Free Radic Biol Med; 2019 Sep; 141():192-204. PubMed ID: 31226399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
